Price · as of 2025
$32.91
Market cap 978.5M
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $104.05 | +216% |
| P/E | -30.67 | |
| P/B | 1.57 | |
| P/S | 2.15 | |
| EV/EBITDA | 42.17 | |
| PEG | — | |
| P/TBV | 2.00 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $32.19 | $240.46 | |||
| 2020 | $64.19 | $46.73 | |||
| 2021 | $39.95 | $102.29 | |||
| 2022 | $19.47 | $15.38 | |||
| 2023 | $20.79 | $33.55 | |||
| 2024 | $20.21 | $347.95 | |||
| 2025 | $25.56 | $34.36 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Castle Biosciences, Inc.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
- CEO
- Derek J. Maetzold
- Employees
- 883
- Beta
- 1.00
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CSTL | Castle Biosciences, Inc. | $32.91 | 978.5M | $34.36 | +4% | -30.67 | 1.57 | 2.15 | 42.17 | — | 2.00 | 79.37% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -233.87% | 3.66% | -22.48% | 3.82% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -11.17 | 16.89 | 1.39 | 4.54 |
| AMN | AMN Healthcare Services, … | $32.80 | 1.27B | $40.83 | +24% | -7.61 | 1.13 | 0.27 | 14.81 | — | -1.83 | 28.35% | 1.21% | -3.51% | -14.19% | 1.96% | -4.24% | 1.25 | 0.73 | 0.94 | 0.82 | 7.61 | -35.58% | -8.49% | -2.38% | 32.12% | 0.47 | 14.59% | 0.00% | 0.00% | 43.95% | 45.14 | 6.40 | 0.55 | 2.45 |
| CDNA | CareDx, Inc | $45.50 | 2.35B | $32.22 | -29% | -42.45 | 2.99 | 2.39 | -162.28 | — | 3.93 | 67.55% | -6.60% | -5.62% | -6.27% | -16.81% | -4.72% | 0.09 | — | 2.86 | 2.45 | 8.43 | -143.01% | 13.79% | 14.43% | 3.98% | 0.47 | 24.22% | 0.00% | 0.00% | 9.68% | -30.13 | 20.91 | 1.99 | 3.65 |
| DRIO | DarioHealth Corp. | $7.66 | 56.01M | $14.96 | +95% | -10.71 | 6.58 | 19.98 | -13.03 | — | -82.17 | 56.64% | -163.94% | -186.56% | -59.62% | -49.81% | -36.44% | 0.47 | -10.91 | 3.73 | 3.10 | -0.16 | -267.57% | -17.31% | -32.60% | -5.84% | -2.78 | -35.45% | 0.00% | 0.00% | 0.00% | -12.34 | -17.34 | 20.22 | -0.01 |
| EMBC | Embecta Corp. | $3.57 | 211.8M | $27.10 | +659% | 7.02 | -1.03 | 0.62 | 6.36 | 33.60 | -0.99 | 62.89% | 30.48% | 8.83% | -13.73% | 39.87% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 20.90% | -3.80% | 816.58% | 27.23% | 0.73 | 31.55% | 5.23% | 36.70% | 26.39% | 5.69 | 10.28 | 1.74 | 2.05 |
| EVH | Evolent Health, Inc. | $3.08 | 346.44M | $8.01 | +160% | -0.59 | 0.82 | 0.18 | -3.26 | -0.11 | -0.40 | 15.14% | -0.24% | -28.49% | -81.81% | -0.32% | -26.08% | 2.38 | -0.08 | 1.31 | 1.23 | -2.32 | 525.93% | -26.56% | -177.59% | 1.39% | 0.10 | 0.34% | 3.26% | -1.90% | 14.97% | -265.91 | 248.02 | 0.63 | 0.23 |
| FLGT | Fulgent Genetics, Inc. | $18.53 | 526.26M | $145.89 | +687% | -7.38 | 0.41 | 1.41 | -2.75 | -18.57 | 0.48 | 40.56% | -28.23% | -18.75% | -5.49% | -9.62% | -5.07% | 0.01 | -1214.61 | 6.48 | 5.03 | 0.93 | 39.72% | 13.83% | 545.09% | -27.32% | -1.20 | -14.90% | 0.00% | 0.00% | 3.06% | -1.39 | -1.02 | 0.39 | 3.64 |
| GERN | Geron Corporation | $1.63 | 1.05B | $20.93 | +1,184% | -12.28 | 4.66 | 5.73 | -18.20 | — | 4.66 | 97.42% | -29.28% | -46.65% | -33.89% | -95.18% | -14.74% | 1.11 | -1.65 | 4.66 | 3.58 | -3.32 | -51.85% | 138.83% | -49.34% | -10.55% | -1.00 | -196.41% | 0.00% | 0.00% | 0.00% | -17.56 | -8.51 | 5.14 | -1.85 |
| MYGN | Myriad Genetics, Inc. | $3.15 | 297.51M | $15.52 | +393% | -1.19 | 1.18 | 0.53 | -1.50 | -0.66 | 2.67 | 69.93% | -8.22% | -44.38% | -68.45% | -10.76% | -42.20% | 0.57 | -6.46 | 2.49 | 1.98 | -0.18 | 180.85% | -1.56% | -33.33% | -5.89% | 0.01 | -4.39% | 0.00% | 0.00% | 0.00% | -7.30 | -19.34 | 0.60 | -0.27 |
| PSNL | Personalis, Inc. | $13.52 | 1.44B | $12.46 | -8% | -7.38 | 2.30 | 8.61 | -5.63 | — | 2.30 | 22.65% | -126.43% | -116.69% | -35.02% | -142.75% | -26.89% | 0.15 | -429.55 | 6.76 | 6.46 | 1.19 | -33.58% | -17.69% | 69.94% | -13.25% | -1.89 | -128.79% | 0.00% | 0.00% | 6.19% | -4.54 | -5.03 | 5.74 | 2.44 |
| VIR | Vir Biotechnology, Inc. | $9.11 | 1.54B | $11.06 | +21% | -2.93 | 1.68 | 18.71 | -2.36 | — | 1.73 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -17.49% | -7.61% | -12.57% | -30.92% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.15 | -2.54 | 14.69 | 0.60 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($104.05 ÷ $32.91) − 1 = +216.17% (IC, example).